Publications by authors named "Mark Heaney"

Claim this Profile
A
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies.
Prabhjot S Mundi, Filemon S Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Mark Heaney

Cancer Discov· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avapritinib versus Placebo in Indolent Systemic Mastocytosis.
Jason Gotlib, Mariana Castells, Hanneke Oude Elberink, Frank Siebenhaar, Karin Hartmann, Mark Heaney

NEJM Evid· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database.
Noa Rippel, Douglas Tremblay, Nicole Zubizarreta, Nikolai Podoltsev, Jason Gotlib, Mark Heaney

Leuk Res· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera.
Douglas Tremblay, Andrew Srisuwananukorn, Lukas Ronner, Nikolai Podoltsev, Jason Gotlib, Mark L Heaney

Hemasphere· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can the treatment of myeloproliferative neoplasms be both good and bad for you?
Mark L Heaney

Lancet Haematol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.
Jason Gotlib, Andreas Reiter, Deepti H Radia, Michael W Deininger, Tracy I George, Mark L Heaney

Nat Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database.
Douglas Tremblay, Lukas Ronner, Nikolai Podoltsev, Jason Gotlib, Mark Heaney

Leuk Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glasdegib in newly diagnosed acute myeloid leukemia.
Shawn M Sarkaria, Mark L Heaney

Expert Rev Anticancer Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase.
John O Mascarenhas, Raajit K Rampal, Heidi E Kosiorek, Rupali Bhave, Elizabeth Hexner, Mark L Heaney

Blood Adv· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.
Stephen T Oh, Moshe Talpaz, Aaron T Gerds, Vikas Gupta, Srdan Verstovsek, Mark L Heaney

Blood Adv· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.
Amer M Zeidan, Prajwal C Boddu, Mrinal M Patnaik, Jan Philipp Bewersdorf, Maximilian Stahl, Mark L Heaney

Lancet Haematol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.
Lukas Ronner, Nikolai Podoltsev, Jason Gotlib, Mark L Heaney, Andrew T Kuykendall

Blood· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.
Gaurav Goyal, Mark L Heaney, Matthew Collin, Fleur Cohen-Aubart, Augusto Vaglio

Blood· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44].
Aaron T Gerds, Tetsuzo Tauchi, Ellen Ritchie, Michael Deininger, Catriona Jamieson, Mark Heaney

Leuk Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.
Aaron T Gerds, Tetsuzo Tauchi, Ellen Ritchie, Michael Deininger, Catriona Jamieson, Mark Heaney

Leuk Res· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.
Alexander C Leeksma, Justin Taylor, Bian Wu, Jeffrey R Gardner, Jie He, Mark L Heaney

Leukemia· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.
Raajit K Rampal, John O Mascarenhas, Heidi E Kosiorek, Leah Price, Dmitriy Berenzon, Mark L Heaney

Blood Adv· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms.
Gabriela S Hobbs, Amritha Varshini Hanasoge Somasundara, Maria Kleppe, Rivka Litvin, Maria Arcila, Mark L Heaney

Haematologica· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis.
Robert J Arceci, Carl E Allen, Ira J Dunkel, Eric Jacobsen, James Whitlock, Mark L Heaney

Pediatr Blood Cancer· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Key Data Elements in Myeloid Leukemia.
Julian Varghese, Christian Holz, Phillip Neuhaus, Massimo Bernardi, Alexandra Boehm, Mark Heaney

Stud Health Technol Inform· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Outcomes in CML Patients Treated With Tyrosine Kinase Inhibitors at a Tertiary Teaching Hospital in South Africa.
Gerhard Sissolak, Jacques Badenhorst, Janami Steenkamp, Mark Heaney, Vernon Louw

Clin Lymphoma Myeloma Leuk· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
Brady L Stein, Stephen T Oh, Dmitriy Berenzon, Gabriela S Hobbs, Marina Kremyanskaya, Mark L Heaney

J Clin Oncol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zeroing in on cereblon.
Mark L Heaney

Eur J Haematol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequencing treatment in chronic myeloid leukemia: the first choice may be the hardest.
Mark L Heaney

Clin Adv Hematol Oncol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.
Eli L Diamond, Lorenzo Dagna, David M Hyman, Giulio Cavalli, Filip Janku, Mark L Heaney

Blood· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis